Free Newsletter
Register for our Free Newsletters
Newsletter
Zones
Advanced Composites
LeftNav
Aerospace
LeftNav
Amorphous Metal Structures
LeftNav
Analysis and Simulation
LeftNav
Asbestos and Substitutes
LeftNav
Associations, Research Organisations and Universities
LeftNav
Automation Equipment
LeftNav
Automotive
LeftNav
Biomaterials
LeftNav
Building Materials
LeftNav
Bulk Handling and Storage
LeftNav
CFCs and Substitutes
LeftNav
Company
LeftNav
Components
LeftNav
Consultancy
LeftNav
View All
Other Carouselweb publications
Carousel Web
Defense File
New Materials
Pro Health Zone
Pro Manufacturing Zone
Pro Security Zone
Web Lec
Pro Engineering Zone
 
 
 
News

Racial disparity found in survival rates of children with a common Leukemia

Yale University : 17 October, 2003  (New Product)
Black, Hispanic and Native American children with Acute Lymphoblastic Leukemia, have worse survival than white and Asian children, even with the availability of modern therapies, Yale researchers report in the October 15 issue of Journal of the American Medical Association.
Led by Principal Investigator Nina Kadan-Lottick, M.D., associate research scientist in pediatrics at Yale School of Medicine, the researchers conducted a population-based study of 5,000 children younger than age 20 who were diagnosed with ALL, the most common childhood malignancy in the United States. They used the National Cancer Institute's Standardized Epidemiology End Result database to determine survival rates according to race and ethnicity. The database includes ethnicity and survival information from nine population centers around the country.

'We found that in the modern treatment era, black and Hispanic children still have worse outcome from leukemia than comparable white children,' said Kadan-Lottick. 'Survival ratio was 1.5 times worse for black children and 1.8 times worse for Hispanic children. The largest difference by race or ethnicity was observed among children diagnosed between ages one and nine years.'

Kadan-Lottick said the reason for the disparity is unclear and further attention is needed to answer this question. The possibilities that must be explored include: differences in response to the same medications, differences in access to care, or differences in compliance with therapy.'

'Previous studies and the current one from St. Jude's are based on the experience of a single referral center,' Kadan-Lottick added. 'The advantage of our study is that it is based on a national population-based registry.'

Kadan-Lottick said that while data from the St. Jude's study is very valuable because it contains much clinical data, it might not be representative of the average American childhood leukemia patient. 'Their patients are provided free care and are self-selected,' she said.
Bookmark and Share
 
Home I Editor's Blog I News by Zone I News by Date I News by Category I Special Reports I Directory I Events I Advertise I Submit Your News I About Us I Guides
 
   © 2012 NewMaterials.com
Netgains Logo